Journal article

Adherence to HIV Treatment Guidelines for Comorbid Disease Assessment and Initiation of Antiretroviral Therapy

Mark Bloch, Jennifer Hoy, Nicola Cunningham, Norman Roth, Michael Bailey, Anna Pierce, Jo Watson, Andrew Carr

JAIDS Journal of Acquired Immune Deficiency Syndromes | LIPPINCOTT WILLIAMS & WILKINS | Published : 2012

University of Melbourne Researchers

Grants

Funding Acknowledgements

Supported by unrestricted study grant from Gilead Sciences.M.Bl. has received research funding from Gilead Sciences, Bristol-Myers Squibb, ViiV Healthcare, Abbott, Janssen and Merck; travel sponsorships from Abbott; Gilead Sciences; GlaxoSmithKline, Janssen and Merck; and has served on advisory boards for Abbott, Merck, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, and Boehringer-Ingelheim. A. C. has received research funding from Baxter, GlaxoSmithKline/ViiV Healthcare, and Merck; consultancy fees from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Merck and Roche; lecture and travel sponsorships from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, and Merck; and has served on advisory boards for Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Merck and Roche. J.H. has received research funding from GlaxoSmithKline/ViiV Healthcare, Gilead Sciences and Merck; travel sponsorships from Janssen-Cilag, Gilead Sciences, and Merck; and has served on advisory boards for Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen-Cilag, Merck and Roche. N.R. has received research funding from ViiV Healthcare, Janssen-Cilag, and Merck; travel sponsorships from Abbott, Gilead Sciences, ViiV Healthcare, and Merck; and has served on advisory boards for Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Merck, Janssen-Cilag, and Boehringer-Ingelheim. A.P. has no conflict of interest. J. W. has served on Advisory Boards for Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen-Cilag, Merck, Pfizer, and Roche.